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Low-grade peripheral inﬂammation is often present in psychotic patients. Toll-like receptors (TLRs) are pattern-recognition
molecules that initiate inﬂammation. Our objective was to investigate the peripheral TLR activity in psychosis. Forty
schizophreniapatients,twentybipolarpatientsandfortyhealthycontrols(HC)wererecruited.Donatedwholebloodwascultured
with TLR agonists for 24h. Cell supernatants were analysed using a multiplex enzyme-linked immunosorbent assay approach to
measure IL-1b, IL-6, IL-8 and tumour necrosis factor-a (TNFa). Plasma was analysed for cytokines, cortisol and acute phase
proteins. Here, we show that selective TLR agonist-induced cytokine (IL-1b, IL-6, IL-8 and TNFa) release is enhanced in
stimulated whole blood from schizophrenia and bipolar patients compared with HC. An exaggerated release of IL-1b, IL-6 and
TNFa following treatment with the TLR2 agonist HKLM was detected in both disorders compared with controls. Enhanced TLR4-
induced increases in IL-1b for both disorders coupled with TNFa increases for bipolar patients were observed. TLR8-induced
increases in IL-1b for both disorders as well as IL-6 and TNFa increases for bipolar patients were detected. TLR9-induced
increases in IL-8 for schizophrenia patients were also observed. No differences in TLR1, TLR3, TLR5, TLR6 or TLR7 activity were
detected. Plasma levels of IL-6 were signiﬁcantly elevated in bipolar patients while TNFa levels were signiﬁcantly elevated in
schizophrenia patients compared with controls. Plasma acute phase proteins were signiﬁcantly elevated in bipolar patients.
These data demonstrate that speciﬁc alterations in TLR agonist-mediated cytokine release contribute to the evidence of immune
dysfunction in psychotic disorders.
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Introduction
Schizophrenia is a psychiatric disorder that affects B1% of
population. The main clinical features are positive symptoms
(delusions, hallucinations and thought disorder), negative
symptoms (social withdrawal and ﬂattening of emotional
responses) and cognitive impairment (attention and memory
deﬁcits).
1,2 There is a strong genetic association
3 and a
common association with prenatal infection.
4 Prenatal infec-
tion (bacterial and viral) and the resulting inﬂammation may
affect development of cortical neurons as demonstrated in rat
models.
5–7 Increasing evidence suggests distinct immunolo-
gical alterations in schizophrenia. These include elevations in
acute phase proteins (haptoglobin, ﬁbrinogen, complement,
acid glycoprotein and hemopexin),
8 and alterations in plasma
pro-inﬂammatory cytokines such as IL-1RA, sIL2R and IL-6
have also been reported.
9
Bipolar disorder represents a category of mood disorders
deﬁned by episodes of hypomania/mania (feelings of elation
with elevated energy/activity levels and reduced sleep) and
episodes of depression (low mood, anhedonia, low energy
levels, loss of motivation, change of sleep and appetite).
10 It
affects B2% of the general population.
11 For many sufferers,
genetic factors have an important role in the aetiology.
10
In addition, several studies report elevated levels of
pro-inﬂammatory cytokines in bipolar patients compared with
healthy controls (HC). Speciﬁcally, elevated plasma levels of
tumour necrosis factor-a (TNFa),
12–14 interleukin-2 (IL-2) and
interleukin-4 (IL-4)
14,15 have been reported in manic bipolar
patients whereas increases in IL-8
13 and IL-6
14 were reported
in depressed bipolar patients. In line with this inﬂammatory
phenotype, serum chemokine levels were found to be
altered in euthymic bipolar patients, with elevated levels of
C–X–C motif chemokine 10 and lower levels of chemokine
(C–C motif) ligand 24.
16
Toll-like receptors (TLRs) are a pivotal component of the
innate immune system. These receptors comprise of ten
members (TLR1-10) in humans and are activated by various
components of both bacteria and viruses for example, TLR4
binds lipopolysaccharide in gram-negative bacteria and TLR7
binds single-stranded RNA (ssRNA) from viruses as well as
some endogenous proteins.
17 In a cellular context, they are
located both at the cell membrane (TLR1, 2, 4, 5 and 6)
and also on intracellular endosomes (TLR 3, 7, 8 and 9).
The extracellular receptors tend to engage with bacterial
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engage with nucleic acids from bacteria and viruses that have
penetrated the cell.
17 These receptors tend to form homo- or
heterodimers with other TLR members. Following receptor
binding, a cellular protein cascade is initiated, which results in
the activation of NF-kB among other transcription factors,
which in turn transcribes inﬂammatory cytokines.
17 TLRs are
present on various cell types and are found in high numbers
on mucosal surfaces (for example, the colonic and bronchial
epithelium) and also on monocytic cells in peripheral blood.
18
Altered levels of plasma inﬂammatory cytokines in schizo-
phreniaandbipolarpatientsledustoinvestigateifalteredTLR
activity may be a possible cause. Our aim was to characterise
the activity of various TLRs in peripheral blood in psychotic
patients.
Materials and methods
Subject population. The study protocol (APC021 2009),
including all procedures, was approved by the Cork
University Hospital ethics committee. Forty HC were
recruited from laboratory or hospital staff. Forty
schizophrenia patients and twenty bipolar patients aged
between 18–65 years of age, who satisﬁed DSM-IV
(diagnostic and statistical manual of mental disorders)
criteria for the diagnosis of schizophrenia and bipolar
disorder (based on a structured clinical interview), were
recruited from psychiatric clinics and inpatient wards at Cork
University Hospital. Individuals with inﬂammatory diseases,
coeliac disease, lactose intolerance, immunodeﬁciency and
individuals who had undergone any abdominal surgery, with
the exception of hernia repair and appendectomy were
excluded. Each potentially eligible patient donated 20ml
venous blood (between 09:00–12:00h), and was evaluated
by psychiatrist using a full review of clinical history, including
current health status, body mass index, family history,
current medication and psychiatric evaluation.
Questionnaires and psychiatric rating scales. In the
schizophrenia cohort, symptoms were objectively rated by
a psychiatrist according to the administered positive and
negative symptom scale (PANSS). This is a 30-item scale
that measures positive symptoms, negative symptoms, their
differential and general psychopathology symptoms. Total
overall scores range from 30 to 210, with a cutoff of p60 for
mild illness severity, 61 to p75 for moderate severity and
475 for markedly severe illness.
19,20 The Calgary
depression scale for schizophrenia was also completed for
all patients to assess comorbid depressive symptomatology.
It is an observer-rated scale, with a cutoff of X6 indicating
concurrent depression.
21 In the bipolar cohort, symptoms
were objectively measured using the Young mania rating
scale and the Hamilton depression rating scale. The Young
mania rating scale is a clinician-administered scale that rates
the severity of mania. There are 11 items in total, measuring
symptoms such as elevated mood, irritability, sleep,
behaviour and insight. The total achievable score is 60,
with a score of p7 indicating remission. The Hamilton
depression rating scale is also a clinician-rated scale for
assessing the severity of depression. It consists of 17 items
(including disturbances in mood, sleep, appetite and weight,
anxiety, agitation, somatic symptoms and suicidal ideation).
There is a maximum possible score of 45. A score of p7
indicates remission; 8–13 mild depression; 14–18 moderate
depression; 19–23 severe depression and 424 very severe
depression.
22–24
Plasma isolation and whole-blood culture. Whole blood
(15ml of the 20ml collected) was added to an equal volume
of Histopaque 1077 (Sigma, St Louis, MO, USA) in a sterile
50-ml tube and centrifuged at 400g for 30min at room
temperature. Plasma on the upper layer was transferred to a
separate tube and stored at  801C for future use. Whole
blood (2ml of the 20ml collected) was diluted 1:10 in
Dulbecco’s Modiﬁed Eagle’s Medium (Gibco, Dublin,
Ireland). Blood was aliquoted into 24-well plates, and
cultured in 371C incubator with 5% CO2. Each blood
sample was cultured in Dulbecco’s Modiﬁed Eagle’s
Medium cell culture medium supplemented with 10% Foetal
Calf Serum with or without the following TLR ligands
from Human TLR agonist kit (InvivoGen, San Diego, CA,
USA) for 24h: TLR1/2—palmitoyl-3-cysteine-serine-lysine 4;
TLR2—heat-killed Listeria Monocytogenes; TLR3—
polyriboinosinic polyribocytidylic acid; TLR4—lipopolysa-
ccharide; TLR5—Salmonella typhimurium Flagellin; TLR6/
2—Pam2CGDPKHPKSF (FSL-1); TLR7—Imiquimod;
TLR8—ssRNA40; TLR9—ODN2006. Agonists were
reconstituted in endotoxin-free water (supplied) with a ﬁnal
concentration of 1mgml
 1 except for HKLM (10
8 cells), Poly
I:C 10mgml
 1 and ODN2006 5mM. Each treatment was
carried out in duplicate. After the indicated culture period,
supernatant from both untreated and stimulated cells
was aspirated and stored at  801C for cytokine analysis at
a later date.
Enzyme-linked immunosorbent assay. Measurements of
pro-inﬂammatory cytokines IL-1b, IL-6, IL-8 and TNFa in both
plasma and following TLR agonist stimulation of whole blood
was carried out using the Meso Scale Discovery 4-plex
human pro-inﬂammatory kit II (Meso Scale Discovery,
Gaithersburg, MD, USA). Plasma C-reactive protein and
serum amyloid A were also measured using Meso Scale
Discovery kits. Enzyme-linked immunosorbent assay plates
were analysed using the Sector 2400 imager from Meso
Scale Discovery. This is an ultra-sensitive method, which has
a detection limit for IL-1b of 0.3pgml
 1, IL-6 of 0.3pgml
 1,
IL-8 of 1.0pgml
 1 and TNFa of 0.3pgml
 1. Plasma cortisol
was measured using the cortisol enzyme immunoassay kit
(Assay Designs, Ann Arbor, MI, USA) with a detection limit of
26.99pgml
 1.
Statistical analysis. The sample size was determined by a
power calculation based on our previous data and aimed at
detecting differences between schizophrenia patients,
bipolar patients and HC at the 0.05 level. Enzyme-linked
immunosorbent assay data were expressed as
mean±s.e.m. and plotted as a histogram showing HC,
schizophrenia and bipolar patients for each TLR and cytokine
analysed. All statistical analysis was carried out using
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Translational PsychiatryGraphPad Prism for Windows (Version 5, La Jolla, CA,
USA). Before analysis, the data were examined for normality
using the Kolmogorov–Smirnov test. Plasma cytokine levels
were compared using one-way analysis of variance
(ANOVA) with a Bonferroni post-hoc test, differences were
considered signiﬁcant at Po0.05. Differences between the
schizophrenia, bipolar and control groups for TLR-agonist-
induced release of cytokines were determined using two-way
ANOVA with a Bonferroni post-hoc test.
Results
Demographic data. Demographic data are shown in
Table 1 while information on medications is shown in
Table 2. No signiﬁcant difference was found between the
groups for age (Table 1). A signiﬁcant difference was found
between the groups for weight (P¼0.0008) and, as a result,
for body mass index (P¼0.0026) using ANOVA. The
schizophrenia cohort signiﬁcantly weighed more than HC
(Po0.001) (Table 1). In our cohort of 40 patients with
schizophrenia, 20 patients had mild illness severity, 13 had
moderate and 7 had severe illness severity according to the
above cutoffs using the PANSS rating scale. The average
total score for PANSS was 60.36±2.45, indicating the
average severity was mild.
Of the schizophrenia cohort, 19 patients had a previous
clinical diagnosis of depression according to DSM-IV criteria
compared with 20 of the bipolar cohort and none of the HC.
Using the Calgary depression scale for schizophrenia, a total
of nine of our schizophrenia cohort satisﬁed a diagnosis of
depression according to these criteria.
21 Using the Young
mania rating scale and Hamilton depression rating scale to
assess bipolar symptoms, a total of seven patients were in
disease remission according to cutoffs of p7 on both these
scales. Seven patients scored X8 on the Young mania rating
scale indicating manic relapse. Six patients scored 47 on the
Hamilton depression rating scale indicating depressive
relapse. Within the control group, three had a family history
of depression, compared with nine of the schizophrenia group
and six of the bipolar group. In the schizophrenia group, 11
patients had a family history of mood disorder (2 bipolar
disorder and 9 unipolar depression) while 15 of the bipolar
patients had a family history of mood disorder (9 bipolar
disorderand6unipolardepression).Noneofthecontrolgroup
had a family history of psychosis compared with 11 of the
schizophrenia group and 3 of the bipolar group (Table 1).
Plasma cytokine, acute phase proteins and cortisol
levels. Plasma from HC, schizophrenia and bipolar
patients was analyzed for cytokines, acute phase proteins
and cortisol. ANOVA conﬁrmed that there were no signiﬁcant
differences in the levels of cortisol between groups
(Figure 1a). ANOVA showed a signiﬁcant difference in
plasma IL-6 levels (P¼0.031), IL-8 levels (P¼0.0014) and
TNFa levels (P¼0.0007). Post-hoc tests showed that bipolar
Table 1 Demographic data were collected from medical history
Healthy controls (N¼40) Schizophrenia (N¼40) Bipolar disorder (N¼20)
Age (years) 36.20±1.758 38.33±1.699 38.50±2.630
Sex 13M, 27F 24M, 16F 10M, 10F
Height (m) 1.706±0.01618 1.733±0.01141 1.691±0.02084
Weight (kg) 69.74±2.591 84.01±2.883*** 75.12±2.664
BMI (kgm
 2) 23.89±0.8261 27.94±0.8507** 26.30±0.9255
PANSS total score N/A 60.36±2.45 N/A
YMRS N/A N/A 16±2.517
HDRS N/A N/A 9±2.646
History of depression 0 19 20
Family history psychosis 0 11 3
Family history depression 3 9 6
Family history bipolar 0 2 9
Abbreviations: BMI, body mass index; HDRS, Hamilton depression rating scale; N/A, not applicable; PANSS, positive and negative symptom scale; YMRS, Young
mania rating scale.
Data from psychiatric rating scales are also shown. Data are expressed as mean±s.e.m. Analysis of variance was used to determine signiﬁcant differences.
**Po0.01 vs Ctrl. ***Po0.001 vs Ctrl.
Table 2 Shown is a list of psychiatric medications taken by schizophrenia and
bipolar patients
Schizophrenia Bipolar disorder
One antipsychotic 26 13
Two antipsychotics 13 4
Three antipsychotics 1 0





















Non-benzodiazepine hypnotics 3 4
NARIs, noradrenaline reuptake inhibitors; SNRI, selective noradrenaline
reuptake inhibitors; SSRIs, selective serotonin reuptake inhibitors; TCAs,
tricyclic antidepressants.
This includes the total numbers on antipsychotics and numbers on individual
antipsychotics as well as antidepressants, mood stabilizers and hypnotics.
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compared with HC while schizophrenia patients had
elevated levels of plasma TNFa (Po0.001) compared with
HC (Figure 1b). ANOVA showed signiﬁcant differences in
plasma C-reactive protein levels (P¼0.0028) and serum
amyloid A levels (P¼0.002) between groups. Post-hoc tests
revealed that bipolar patients had elevated plasma levels of
both C-reactive protein (Po0.01) and serum amyloid A
(Po0.001) compared with HC. These differences remain
signiﬁcant when body mass index is added as a covariate.
TLR agonist cytokine release. Supernatants from whole-
blood treatments with TLR agonists of HC, schizophrenia
and bipolar patients were analysed for levels of four different
pro-inﬂammatory cytokines IL-1b, IL-6, IL-8 and TNFa. Two-
way ANOVA demonstrated a signiﬁcant effect of both
disease state (F2, 1903¼25.92, Po0.0001) and TLR
agonist treatment (F9, 1903¼169.5, Po0.0001) with a
signiﬁcant interaction (F18, 1903¼7.05, Po0.0001) between
the two factors for IL-1b levels. A signiﬁcant effect of both
disease state (F2, 1892¼5.81, P¼0.0031) and treatment (F9,
1892¼198.9, Po0.001) with a signiﬁcant interaction (F18,
1892¼4.63, Po0.0001) between the two factors was found
for IL-6 levels. Two-way ANOVA demonstrated a signiﬁcant
effect of both disease state (F2, 1924¼35.69, Po0.0001) and
treatment (F9, 1924¼57.23, Po0.0001) but not a signiﬁcant
interaction (F18, 1924¼1.132, P40.05) between the two
factors for IL-8 levels. A signiﬁcant effect of both disease
state (F2, 1927¼32.44, Po0.0001) and treatment (F9,
1927¼135.8, Po0.0001) with a signiﬁcant interaction (F18,
1927¼8.542, Po0.0001) between the two factors for TNFa
levels was also found.
Post-hoc analysis of individual treatments test revealed
signiﬁcant differences between schizophrenia patients, bipo-
lar patients and HC. In the untreated blood, levels of IL-8 were
found to be signiﬁcantly higher in both schizophrenia
(4562±255pgml
 1; Po0.001) and bipolar disorder patients
(4283±117pgml
 1; Po0.05) compared withHC
(3077±298pgml
 1) (Figure 2a). No signiﬁcant differences
were found in cytokine release following treatment with the
TLR1/2 agonist Pam3Csk (Figure 2b). IL-1b release was
found to be signiﬁcantly elevated in schizophrenia
(1949±167pgml
 1; Po0.001) and bipolar disorder patients
(2597±267pgml
 1; Po0.001) compared with HC blood
(957±114pgml
 1) following treatment with the TLR2 agonist
HKLM. In addition, IL-1b release was signiﬁcantly greater in
bipolar disorder compared with schizophrenia patients
(Po0.001).
IL-6 release was signiﬁcantly elevated in schizophrenia
(2675±259pgml
 1; Po0.05) and bipolar disorder patients
(3810±262pgml
 1; Po0.001) compared with HC blood
(2040±208pgml
 1). In addition, IL-6 release was signiﬁ-
cantly greater in bipolar disorder compared with schizophre-
nia patients (Po0.001). TNFa release was found to be
signiﬁcantly elevated in schizophrenia (2197±247pgml
 1;
Po0.001) and bipolar disorder patients (3753±461pgml
 1;
Po0.001) compared with HC blood (1134±164pgml
 1). In
addition, TNFa release was greater in bipolar disorder
patients compared schizophrenia patients (Po0.001)
(Figure 2c).
No signiﬁcant differences were found in cytokine
release following treatment with the TLR3 agonist Poly I:C
(Figure 2d). IL-1b was found to be signiﬁcantly elevated in
schizophrenia (2409±181pgml
 1; Po0.05) and bipolar
disorder patients (2859±260pgml
 1; Po0.001) compared
with HC (1961±131pgml
 1) following treatment with the
TLR4 agonist lipopolysaccharide. IL-8 release was signiﬁ-
cantly lower in bipolar disorder patients (4875±77pgml
 1)
compared with schizophrenia blood (6146±231pgml
 1).
TNFa release was found to be signiﬁcantly elevated in
bipolar disorder patients (3332±376pgml
 1; Po0.001)
Figure 1 Shown is a graph of plasma (a) cortisol, (b) cytokine and (c) acute
phase protein levels in healthy controls (Ctrl), schizophrenia (Scz) and bipolar (BP)
patients measured using enzyme-linked immunosorbent assay. Data shown are
expressed as mean±s.e.m. Statistical differences between groups were
determined using ANOVA. *Po0.05, **Po0.01, ***Po0.001 vs Ctrl. CRP,
plasma C-reactive protein; SAA, serum amyloid A.
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Translational Psychiatrycompared with HC blood (2361±164pgml
 1). In addition,
TNFa release was signiﬁcantly greater in bipolar disorder
patients compared with schizophrenia blood (Po0.05)
(Figure 2e).
No signiﬁcant differences in cytokine release compared
with controls were found following treatment with the TLR5
agonistﬂagellin.However,IL-8releasewassigniﬁcantlylower
in bipolar disorder patients (4690±89pgml
 1; Po0.05)
compared with schizophrenia (5934±247pgml
 1). In addi-
tion, TNFa release was greater in bipolar disorder patients
(1860±375pgml
 1; Po0.05) compared with schizophrenia
(1196±121pgml
 1) (Figure 3a). No signiﬁcant differences in
cytokine release were found following treatment with the
TLR6/2 agonist FSL1 (Figure 3b) or the TLR7 agonist
Imiquimod (Figure 3c). IL-1b release was found to be
signiﬁcantly elevated in schizophrenia (1835±203pgml
 1;
Po0.001) and bipolar disorder patients (2282±232pgml
 1;
Po0.001) compared with HC (1181±120pgml
 1) following
treatment with the TLR8 agonist ssRNA40.
IL-6 release was found to be signiﬁcantly elevated in bipolar
disorder (2484±253pgml
 1; Po0.05) compared with con-
trols (1631±152pgml
 1). In addition, IL-6 release was
greater in bipolar disorder compared with schizophrenia
patients(Po0.01).TNFareleasewasfoundtobesigniﬁcantly
elevated in bipolar disorder patients (2472±323pgml
 1;
Po0.001) compared with controls (1132±117pgml
 1)
following treatment with the ssRNA40. In addition, TNFa
release was greater in bipolar disorder compared with
schizophrenia patients (Po0.01) (Figure 3d). IL-8 release
was found to be signiﬁcantly elevated in schizophrenia
patients (2255±339pgml
 1; Po0.05) compared with con-
trols (1104±276pgml
 1) following treatment with the TLR9
agonist ODN2006. In addition, IL-8 release was lower in
bipolar disorder compare with schizophrenia patients
(Po0.05) (Figure 3e). Entering body mass index as a
covariate did not alter the signiﬁcance of the ﬁndings.
Discussion
The exact pathophysiology of schizophrenia and bipolar
disorder is still unknown. Immune activation has been
reported in a number of studies for both disorders, showing
increases in particular pro-inﬂammatory cytokines.
9,12,13
Whether this is central to disease progression or is an
epiphenomenon is unclear. The cause of the elevations in
certain cytokines seen in schizophrenia and bipolar patients
has yet to be determined. We hypothesized that TLR activity
may be altered in psychiatric patients.
Figure2 ShownisagraphofIL-1b,IL-6,IL-8andTNFalevelsinstimulatedwhole-bloodsupernatantstakenfromHC(Ctrl),schizophrenia(Scz)andbipolar(BP)patients
measuredusingenzyme-linkedimmunosorbentassayfollowing(a)notreatmentortreatmentwiththe(b)TLR1/2agonistPam3Csk,(c)TLR2agonistHKLM,(d)TLR3agonist
Poly I:C or (e) TLR agonist lipopolysaccharide for 24h. Data shown are expressed as mean±s.e.m. Statistical differences between treatments and disease states were
determined using two-way ANOVA with Bonferroni post-hoc test. *Po0.05, ***Po0.001 vs Ctrl;
#Po0.05,
##Po0.01,
###Po0.001 bipolar disorder vs schizophrenia.
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shown to have elevated plasma cytokines and acute phase
proteins. The effects of elevated cytokine levels on the
pathophysiology of these disorders remain to be precisely
deﬁned. Cytokines are known to have an effect on the HPA
axis and stress response.
25 IL-1b, IL-6 and TNFa have all
been reported to stimulate secretion of corticotrophin-releas-
ing hormone in rat as well as in humans.
26,27 Cytokines are
thought to be able to cross the blood–brain barrier or, at least,
stimulate cells at the barrier to release more cytokines within
the brain.
27 During development and especially following
maternal infection and inﬂammation, cytokines have been
reported to affect cortical neuronal development,
6,28 and, by
so doing, may have a sustainable effect.
Whole-blood stimulations revealed a distinct pattern of
peripheral TLR activity in both schizophrenia and bipolar
patients. It was apparent that the exaggerated effects of
HKLM, the TLR2 agonist, were the most striking result in both
disorders, with TLR4 and TLR8 activities also enhanced. No
differences in TLR1, TLR3, TLR5, TLR6 or TLR7 activity were
detected compared with controls. It is known that TLR2 may
bind a number of different ligands, especially lipopeptides
related to bacterial cell wall components in addition to
endogenously released peptides,
29 although a yet undiscov-
ered endogenous or exogenous ligand(s) may also activate
this receptor. In this study, we showed that the TLR2
homodimer activity (HKLM) was enhanced as distinct from
activities of the TLR1/2 (Pam3Csk) or TLR6/2 (FSL1)
heterodimers. It is unclear if ligand(s) for TLRs are present
in blood from schizophrenia and bipolar patients under basal
conditions, which would have the ability to activate these
receptors.
Schizophreniaandbipolardisorderaresimilarinrespectsto
epidemiology, in particular age of onset, incidence in the
population and lifetime duration.
30 In addition, it has become
apparent from a number of studies that these disorders share
some molecular susceptibility loci.
30,31 As mentioned before,
these disorders both display increases in plasma levels of
inﬂammatory markers. At present, it is not certain why
schizophrenia and bipolar patients display greater TLR
activity compared with controls or why their pattern is so
similar. It has been shown that schizophrenia and bipolar
patients appear to be particularly susceptible to stress.
32–36 It
is apparent from both animal models and clinical studies that
chronic stress may affect the immune response.
37 It was
reported that repeated social defeat stress enhanced the
Figure3 ShownisagraphofIL-1b,IL-6,IL-8andTNFalevelsinstimulatedwhole-bloodsupernatantstakenfromHC(Ctrl),schizophrenia(Scz)andbipolar(BP)patients
measured using enzyme-linked immunosorbent assay following treatment with (a) TLR5 agonist Flagellin, (b) TLR6/2 agonist FSL1, (c) TLR7 agonist Imiquimod, (d) TLR8
agonist ssRNA40 or (e) TLR9 agonist ODN2006 for 24h. Data shown are expressed as mean±s.e.m. Statistical differences between treatments and untreated were
determined using two-way ANOVA with Bonferroni post-hoc test. *Po0.05, ***Po0.001 vs Ctrl;
#Po0.05,
##Po0.01, bipolar disorder vs schizophrenia.
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increase in the expression of TLR2 and TLR4.
38 The same
group also showed that social defeat may activate splenic
dendritic cells and enhances TLR activity on these cells as
assessed by cytokine output by ligand stimulation.
39 In
addition, chronic restraint stress has been shown to result in
immune suppression and this was mediated by TLR4.
40,41
It has been shown that cytokines themselves can alter TLR
expression.
42,43 Plasma cytokines and acute phase proteins
have been shown to be elevated in this cohort of patients and
this potentially may explain why there are increases in TLR
activity in these patients. Although a number of psychiatric
disorders have alterations in the immune system, TLR activity
may allow us to differentiate between different disorders, with
individual disorders having their own signature TLR increases
and decreases. This may lend peripheral TLR activity as a
potential biomarker in the diagnosis of psychiatric disorders.
The average weight of the schizophrenia cohort was higher
than HC. This may be due to antipsychotic drugs, which have
been shown to induce weight gain in some patients,
44 but
it does not account for the enhanced immune responses in
this study.
We have observed in some instances where there are
greater increases in a cytokine following ligand stimulation in
one disorder over another. A possible explanation forthis may
be owing to expression or activity differences between
disorders of one of the many downstream signalling mole-
cules that lead to activation of transcription factors following
TLR stimulation. Alternatively, it may be for epigenetic
reasons, such as decreased transcriptional activity in either
disorder for particular cytokines. This would imply that when a
ligand activates the receptor and initiates the downstream
signalling pathway, there would be less transcriptional activity
at the promoter of the given cytokine due to epigenetic
silencing/modiﬁcations.
Limitations of this study include the lack of drug-free
patients.This mayhave implicationsfortheobserved immune
changesinschizophrenia andbipolarpatients. Itisknownthat
antipsychotics may have an effect on plasma cytokine
levels.
45 As a sizeable number of patients were on one or
more antipsychotics in the schizophrenia cohort and a mood
stabilizer and/or antipsychotics in the bipolar cohort (Table 2),
it would be difﬁcult to assess the effect of individual drugs on
TLR activity. In addition, bipolar patients were not selected on
the basis of the phase of the disorder, and so differences may
exist between manic and depressive patients, however, the
study is not powered to detect these differences. Similarly,
schizophrenia patients were not differentiated on illness
severity.
This study has provided novel insights into relationships
between TLR activation, plasma cytokine levels and clinical
phenotype among a well-characterised group of schizophre-
nia and bipolar patients. While conﬁrming that certain pro-
inﬂammatory cytokine levels are increased in plasma among
schizophrenia and bipolar patients, we have gone on to
describe, what is to our knowledge for the very ﬁrst time,
distinctivepatternsofTLRactivityintheperipheryofpsychotic
patients. In summary, the observed increase in TLR activity in
psychiatric patients implies that following engagement of
these receptors by endogenous or exogenous ligands, there
would be a greater release of inﬂammatory cytokines in
psychiatric patients. This increase in inﬂammation may in turn
affect neuronal plasticity as has been demonstrated using
animal models.
5–7 This study further suggests a link between
inﬂammation and psychosis.
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